News
Pfizer (NYSE:PFE) Gets CDC Recommendation to Expand ABRYSVO Vaccine Use for RSV Prevention
Pfizer (NYSE:PFE) recently received a CDC recommendation for wider use of its RSV vaccine, ABRYSVO, in adults aged 50-59 at increased risk. Despite this positive development, Pfizer's shares saw a 2% decline over the past week.
Pfizer (NYSE:PFE) and GSK (NYSE:GSK) are expected to reap benefits as an advisory committee of the CDC on Wednesday voted to ...
A year after narrowing its recommendation for who should use vaccines to defend against respiratory syncytial virus (RSV), a ...
The Advisory Committee on Immunisation Practices (ACIP) has voted to widen the recommendations on the use of RSV shots to ...
Pfizer's strong R&D pipeline, 7.5%+ dividend yield, & undervalued PE ratio make PFE stock a compelling investment opportunity ...
A three-year study has found robust evidence that one particular vaccine for respiratory syncytial virus (RSV) offers older ...
Major study shows that adults with respiratory syncytial virus-associated acute respiratory infection face a 2.7-fold higher ...
Vaccine makers targeting COVID-19 to measles will come under investor scrutiny on Tuesday as a group of independent experts at the CDC are scheduled to meet for the first time to review U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback